Epigral Ltd Q1 FY26 – ₹607 Cr Sales, ₹160 Cr PAT, EPS ₹37.2: Chemicals ki CPVC-ECH Factory Se CFO Ne Exit Liya, Investors Ko Mileage?
1. At a Glance
Epigral ne Q1 FY26 mein ₹607 Cr ki sales ke saath ₹160 Cr ka profit chhapa diya, matlab 86% profit growth despite sales thoda gir gaya. EPS ₹37.2, jo quarter mein itna tez bhaaga ki Sensex ke joggers bhi sharma gaye. CFO ne September tak resignation de diya – kyunki shayad woh bhi soch raha hoga, “Boss, CPVC aur Epichlorohydrin se zyada mera stress polymer ho gaya hai.”
2. Introduction
Picture this: Ek chemical company jo pehle Meghmani Finechem ke naam se jaati thi, ab fancy rebrand karke “Epigral” ban gayi. Matlab wahi purana dal, naye dabbe mein — thoda stylish, thoda corporate.
Epigral ka Dahej plant ekdum “desi Tesla Gigafactory” jaisa hai — backward + forward integration, bas difference itna hai ki yeh chlorine aur hydrogen banata hai, not EVs. India mein sabse pehla Epichlorohydrin (ECH) plant unhone set kiya. CPVC resin plant toh aisa lagta hai jaise Astral Pipes ka private jagir hi khol liya ho.
Lekin saari masti ke beech ek badi problem hai: realizations gir gaye 12-45% tak FY24 mein. Matlab “volume toh badao, price toh gir raha hai” wali Ramayana chal rahi hai. Topline -9% thi FY24, par PAT abhi bhi ₹431 Cr aa gaya. “Margin contraction? Arre yeh chemicals hain boss, thoda leak toh chalta hai.”
Aur ab sabse bada question: Specialty aur derivatives ka contribution 25% (FY22) se 56% (H1FY25) tak le aaye hain. By FY27, 70% banana chahte hain. Matlab plain soda bechne se ab cocktail mixologist banna hai.
3. Business Model – WTF Do They Even Do?
Epigral basically ek chemical ka thali hai:
Chlor-Alkali: Caustic soda aur caustic potash, industrial ke namak-mirch. Iska share gir raha hai – 75% FY22 → 44% H1FY25.
Derivatives & Specialty: CPVC, ECH, chloromethanes, hydrogen peroxide. Iska share upar chadh raha hai – 25% → 56%.
CPVC resin aur CPVC compound demand abhi booming hai, kyunki har builder ko Astral Pipes chahiye. Aur Epichlorohydrin toh basically epoxy resins ka baap. Matlab ghar banane se leke pharma aur paints tak sabko unki “chemical ki jadoo ki jhappi” lagti hai.
Client list mein Vedanta, SRF, Divis, Astral Pipes – matlab “who’s who of India Inc” bhi customer hai.
Par haan, yeh sab padke tum soch rahe hoge: “Boss, chemicals toh sab banate hain, Epigral special kya hai?” Answer: backward integration + scale + CPVC aur ECH ke India ke sabse bade plant. Matlab monopoly-ish thoda feel aata hai.
4. Financials Overview
Quarterly Performance (₹ Cr)
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
607
651
628
-6.8%
-3.3%
EBITDA
163
176
173
-7.4%
-5.8%
PAT
160
86
87
+86.5%
+84.0%
EPS (₹)
37.2
20.7
20.1
+79.7%
+85.1%
Commentary: Sales thoda pichka gaya, par profit double ho gaya. Matlab jaise Bollywood movie flop ho jaaye but actor ka Instagram follower double ho. PAT margin ab 26% ke upar aake “Boss mode” on kar diya. EPS ka annualized ₹148 banta hai, aur CMP ₹1763 pe P/E ~11.9. Industry ka P/E 33.2 hai. Matlab market abhi tak sasta maal ignore kar raha hai, ya phir ekdum “dikh raha hai par maan nahi raha.”
Tumhare hisaab se market sahi kar raha hai ya bas chemicals sector ko punish mode mein daal diya hai?
5. Valuation Discussion – Fair Value Range
Method 1: P/E Multiple
Annualized EPS = ₹37.2 × 4 = ₹148.8
Assign fair range P/E = 15–22 (peer group ka 33 dekh ke conservative liya).
Fair value = ₹2,230 – ₹3,270
Method 2: EV/EBITDA
TTM EBITDA ~₹698 Cr, EV ~₹8,177 Cr
EV/EBITDA current ~11.7×
Fair range = 12–16× → EV = ₹8,376 – ₹11,168 Cr
Minus net debt ₹593 Cr → Equity value = ₹7,783 – ₹10,575 Cr
